Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous ... are not currently approved for any indications, raising concerns about the potential for regulatory hurdles ...

Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by ...

Regeneron Pharmaceuticals Inc (REGN) reports robust growth in Dupixent sales and strategic R&D investments, while navigating ...

While gaining momentum in the crowded NSCLC immunotherapy market is likely to be a challenge, Sanofi and Regeneron are hoping to carve out a niche for Libtayo in indications like BCC and cervical ...

Clinical Trial Supply Agreement Announced with Regeneron for Libtayo (cemiplimab): In February ... designed to improve tolerability and expand indications to include RAS-driven tumors such ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

The indication is based on a phase 3 trial – Empower-Lung 1 – that showed Libtayo given as a monotherapy cut the risk of death by 43% compared to chemotherapy in advanced, PD-L1-high patients ...